Middle East Pharmaceutical Industries Company (TADAWUL:4016)
Saudi Arabia
· Delayed Price · Currency is SAR 103.50
+0.60 (0.58%)
Apr 29, 2026, 3:15 PM AST
TADAWUL:4016 Income Statement
Financials in millions SAR. Fiscal year is January - December.
Millions SAR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 |
| Revenue | 460.48 | 394 | 338.44 | 302.66 | 287.22 | Upgrade
|
| Revenue Growth (YoY) | 16.87% | 16.42% | 11.82% | 5.38% | -4.79% | Upgrade
|
| Cost of Revenue | 174.71 | 151.59 | 134.74 | 119.21 | 113.47 | Upgrade
|
| Gross Profit | 285.78 | 242.41 | 203.7 | 183.45 | 173.76 | Upgrade
|
| Selling, General & Admin | 177.35 | 150 | 127.59 | 113.73 | 97.74 | Upgrade
|
| Other Operating Expenses | 0.02 | -0.42 | 0.09 | 0.18 | -0.14 | Upgrade
|
| Operating Expenses | 178.84 | 153.12 | 126.17 | 114.04 | 97.6 | Upgrade
|
| Operating Income | 106.93 | 89.29 | 77.53 | 69.41 | 76.16 | Upgrade
|
| Interest Expense | -3.25 | -3.67 | -5.75 | -4.73 | -1.87 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.02 | -0.04 | -0.47 | 0.27 | - | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | - | -1.08 | Upgrade
|
| EBT Excluding Unusual Items | 103.7 | 85.58 | 71.31 | 64.95 | 73.22 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | -2.76 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.04 | 0.12 | 0.13 | 0.08 | - | Upgrade
|
| Pretax Income | 103.74 | 86.35 | 71.44 | 65.02 | 70.46 | Upgrade
|
| Income Tax Expense | 6.73 | 6.5 | 5.61 | 5.57 | 4.18 | Upgrade
|
| Net Income | 97.01 | 79.85 | 65.83 | 59.45 | 66.28 | Upgrade
|
| Net Income to Common | 97.01 | 79.85 | 65.83 | 59.45 | 66.28 | Upgrade
|
| Net Income Growth | 21.49% | 21.30% | 10.72% | -10.31% | -8.97% | Upgrade
|
| Shares Outstanding (Basic) | 20 | 20 | 20 | 20 | 20 | Upgrade
|
| Shares Outstanding (Diluted) | 20 | 20 | 20 | 20 | 20 | Upgrade
|
| EPS (Basic) | 4.85 | 3.99 | 3.29 | 2.97 | 3.31 | Upgrade
|
| EPS (Diluted) | 4.85 | 3.99 | 3.29 | 2.97 | 3.31 | Upgrade
|
| EPS Growth | 21.49% | 21.30% | 10.72% | -10.31% | -8.97% | Upgrade
|
| Free Cash Flow | 73.74 | 21.91 | 71.82 | 58.99 | 25.28 | Upgrade
|
| Free Cash Flow Per Share | 3.69 | 1.09 | 3.59 | 2.95 | 1.26 | Upgrade
|
| Dividend Per Share | - | 2.000 | - | - | - | Upgrade
|
| Gross Margin | 62.06% | 61.52% | 60.19% | 60.61% | 60.50% | Upgrade
|
| Operating Margin | 23.22% | 22.66% | 22.91% | 22.93% | 26.52% | Upgrade
|
| Profit Margin | 21.07% | 20.27% | 19.45% | 19.64% | 23.08% | Upgrade
|
| Free Cash Flow Margin | 16.01% | 5.56% | 21.22% | 19.49% | 8.80% | Upgrade
|
| EBITDA | 119.12 | 99.08 | 85.14 | 76.25 | 82.86 | Upgrade
|
| EBITDA Margin | 25.87% | 25.15% | 25.16% | 25.19% | 28.85% | Upgrade
|
| D&A For EBITDA | 12.19 | 9.8 | 7.61 | 6.84 | 6.7 | Upgrade
|
| EBIT | 106.93 | 89.29 | 77.53 | 69.41 | 76.16 | Upgrade
|
| EBIT Margin | 23.22% | 22.66% | 22.91% | 22.93% | 26.52% | Upgrade
|
| Effective Tax Rate | 6.49% | 7.53% | 7.85% | 8.57% | 5.93% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.